NCT06402812Completed
The Perceived Mismatch Between Dose Recommendations of PKI's and the Clinical Practice
Source: ClinicalTrials.gov · Last updated 7 May 2024
Brief summary (registry, in English)
A qualitative research study will be conducted using semi-structured interviews. The target population includes regulators involved in the registration of PKIs and healthcare professionals who use PKIs in clinical practice. Participants will be recruited until a rich understanding of the subject is reached.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 18 (actual)
- First submitted
- 29 Apr 2024
- Start date
- 6 Feb 2024
- Primary completion date
- 1 Mar 2024
- Lead sponsor
- University Medical Center Groningen
- Diseases
- Childhood cancers
- NCT number
- NCT06402812
What you commit to
- Study type: Observational
- Participants enrolled: 18
- From 6 Feb 2024 to the primary completion date, 1 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- No exclusion criteria will be maintained.
Who the study is looking for
- \- Regulators involved in the regulation of oncolytic products. Healthcare professionals who prescribe PKI's as a treatment for cancer in clinical practice (e.g. oncologists).
Age in the registry: 16 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Medical Center Groningen Coordinator of this site? Confirm its status | Groningen | Netherlands | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.